Graft Outcome and Mycophenolic Acid Trough Level Monitoring in Kidney Transplantation

Transplantation Proceedings

Volumn 41, Issue 6, 2009, Pages 2102-2103

  Sanchez Fructuoso A I ^a   de la Higuera, M A Moreno ^a   Garcia Ledesma, P ^a   Giorgi, M ^a   Ramos, F ^a   Calvo, N ^a   Perez Flores I ^a   Barrientos, A ^a  

^a HOSPITAL CLÍNICO SAN CARLOS   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; CREATININE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS;

ACUTE GRAFT REJECTION; ARTICLE; CORTICOSTEROID THERAPY; CREATININE CLEARANCE; DELAYED GRAFT FUNCTION; DRUG BLOOD LEVEL; DRUG MONITORING; ENZYME MULTIPLIED IMMUNOASSAY TECHNIQUE; GASTROINTESTINAL TOXICITY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

ANTIBIOTICS, ANTINEOPLASTIC; DRUG MONITORING; FOLLOW-UP STUDIES; GRAFT REJECTION; HUMANS; KIDNEY TRANSPLANTATION; MYCOPHENOLIC ACID; RETROSPECTIVE STUDIES;

EID: 68949205633     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2009.06.001     Document Type: Article

References (12)

1. Srinivas T.R., Kaplan B., Schold J.D., et al. The impact of mycophenolate mofetil on long-term outcomes in kidney transplantation. Transplantation 80 2 suppl (2005) S211
2. van Gelder T., Le Meur Y., Shaw L.M., et al. Therapeutic drug monitoring of mycophenolate mofetil in transplantation. Ther Drug Monit 28 (2006) 145
3. van Gelder T., Hilbrands L.B., Vanrenterghem Y., et al. A randomized double blind, multicenter plasma concentration study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation. Transplantation 68 (1999) 261
4. Hale M.D., Nicholls A.J., Bullingham R.E., et al. The pharmacokinetic-pharmacodynamic relationship for mycophenolate mofetil in renal transplantation. Clin Pharmacol Ther 64 (1998) 672
5. Shaw L.M., Holt D.W., Oellerich M., et al. Current issues in therapeutic drug monitoring of mycophenolic acid: report of a roundtable discussion. Ther Drug Monit 23 (2001) 305
6. Van Hest R.M., van Gelder T., Vulto A.G., et al. Population pharmacokinetics of mycophenolic acid in renal transplant recipients. Clin Pharmacokinet 44 (2005) 1083
7. Hesselink D.A., Van Hest R.M., Mathot R.A., et al. Cyclosporine interacts with mycophenolic acid by inhibiting the multidrug resistance-associated protein 2. Am J Transplant 5 (2005) 987
8. Borrows R., Chusney G., Loucaidou M., et al. Mycophenolic acid 12-h trough level monitoring in renal transplantation: association with acute rejection and toxicity. Am J Transplant 6 (2006) 121
9. Le Meur Y., Büchler M., Thierry A., et al. Individualized mycophenolate mofetil dosing based on drug exposure significantly improves patient outcomes after renal transplantation. Am J Transplant 7 (2007) 2496
10. van Gelder T., Silva H.T., de Fijter J.W., et al. Comparing mycophenolate mofetil regimens for de novo renal transplant recipients: the fixed-dose concentration-controlled trial. Transplantation 86 (2008) 1043
11. Arns W., Cibrik D.M., Walker R.G., et al. Therapeutic drug monitoring of mycophenolic acid in solid organ transplant patients treated with mycophenolate mofetil: review of the literature. Transplantation 82 (2006) 1004
12. Elbarbry F.A., and Shoker A.S. Therapeutic drug measurement of mycophenolic acid derivatives in transplant patients. Clin Biochem 40 (2007) 752